Phase 2 Study of Neoadjuvant Treatment with Cellular Redox Modulator NOV-002 in Combination with Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) in Patients with Stage II-III HER-2 (-) Breast Cancer

被引：0
|
作者：
Montero, A. J.
Diaz, C. M.
Slingerland, J.
Pegram, M.
Hurley, J.
Welsh, C. F.
Avisar, E.
Seo, P.
Vogel, C. L.
Garrett-Mayer, E.
Hermann, V.
Baker, M. K.
Silva, O.
Koniaris, L.
Rodgers, S.
Schuhwerk, K.
Pazoles, C. J.
Moffat, F.
Cole, D. J.
Gluck, S.
机构：
[1] Univ Miami, Sylvester Comprehens Canc Ctr, Coral Gables, FL 33124 USA
[2] Med Univ S Carolina, Charleston, SC USA
[3] Novelos Therapeut, Newton, MA USA
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P1-11-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-05
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Comparison of the efficacy and safety of the EC-T (epirubicin/cyclophosphamide followed by docetaxel) and TCb (docetaxel/carboplatin neoadjuvant regimens in early TOP2A-normal stage II-III breast cancer
    Li, W. P.
    Zhu, T.
    Hu, M. X.
    Yang, M.
    Ji, F.
    Gao, H. F.
    Yang, C. Q.
    Zhang, L. L.
    Cheng, M. Y.
    Xu, F. P.
    Wang, K.
    NEOPLASMA, 2020, 67 (06) : 1409 - 1415
  • [22] Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer
    Rocca, Andrea
    Cortesi, Pietro
    Cortesi, Laura
    Gianni, Lorenzo
    Matteucci, Federica
    Fantini, Lorenzo
    Maestri, Antonio
    Giunchi, Donata Casadei
    Cavanna, Luigi
    Ciani, Rosa
    Falcini, Fabio
    Bagni, Antonella
    Meldoli, Elena
    Dall'Agata, Monia
    Volpi, Roberta
    Andreis, Daniele
    Nanni, Oriana
    Curcio, Annalisa
    Lucchi, Leonardo
    Amadori, Dino
    Fedeli, Anna
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [23] A phase I study of neoadjuvant chemotherapy with nanoparticle albumin-bound paclitaxel, doxorubicin, and cyclophosphamide (NAC) in patients with stages II-III HER2-negative breast cancer
    Khong, H. T.
    Dyess, D. L.
    Butler, T. W.
    Dumlao, T. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
    Wang, Haoqi
    Li, Yuntao
    Qi, Yixin
    Zhao, Erbao
    Kong, Xiangshun
    Yang, Chao
    Yang, Qiqi
    Zhang, Chengyuan
    Liu, Yueping
    Song, Zhenchuan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer
    Lynce, Filipa
    Yeh, Eren D.
    Regan, Meredith M.
    Qin, Lei
    Bay, Camden P.
    Krop, Ian
    Harrison, Beth T.
    Nakhlis, Faina
    Bellon, Jennifer
    Overmoyer, Beth
    CANCER RESEARCH, 2022, 82 (04)
  • [26] Efficacy results of node-negative HER2-amplified breast cancer subset from BCIRG 006 study: A phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin, and trastuzumab (TCH).
    Valero, V.
    Slamon, D. J.
    Eiermann, W.
    Robert, N. J.
    Pienkowski, T.
    Martin, M.
    Mackey, J. R.
    Lindsay, M. A.
    Bee-Munteanu, V.
    Press, M. F.
    Sauter, G.
    Crown, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Doxorubicin and cyclophosphamide followed by weekly docetaxel (AC-T) as neoadjuvant chemotherapy in operable breast cancer patients:: GEICAM 2002-03 Study
    Estévez, LG
    Adrover, E
    Barnadas, A
    Cuevas, JM
    Seguí, MA
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S229 - S229
  • [28] Phase II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab combination as first line treatment of patients with her-2/neu positive locally advanced or metastatic breast cancer
    Amadori, D.
    Gasparini, G.
    Ardizzoni, A.
    Comella, G.
    Saracchini, S.
    Barone, C.
    Bordonaro, R.
    Djazouli, K.
    Barbalo, A.
    CANCER RESEARCH, 2009, 69 (02) : 247S - 247S
  • [29] A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast Cancer
    Yardley, Denise A.
    Shipley, Dianna
    Zubkus, John
    Wright, Gail L.
    Ward, Patrick J.
    Mani, Aruna
    Shastry, Mythili
    Finney, Lindsey
    DeBusk, Laura
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2019, 19 (01) : 1 - 9
  • [30] A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer
    Werner, Theresa L.
    Ray, Abhijit
    Lamb, John G.
    VanBrocklin, Matthew
    Hueftle, Kristin
    Cohen, Adam L.
    Beck, Anna C.
    Buys, Saundra S.
    Dyess, Donna L.
    Butler, Thomas W.
    Dumlao, Theresa L.
    Neumayer, Leigh
    Khong, Hung T.
    CLINICAL BREAST CANCER, 2017, 17 (07) : 503 - 509
12345